Advertisement
Screener

RHYTHM PHARMACEUTICALS, INC. (RYTM) Stock-Based Compensation

2.8 / 5 stars · 68/120 Roast Me

RHYTHM PHARMACEUTICALS, INC. Stock-Based Compensation

RHYTHM PHARMACEUTICALS, INC. (RYTM) reported Stock-Based Compensation of $49.16 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.

Financial Statements › Cash Flow › Operating Activities

us-gaap:ShareBasedCompensation · last filed 2026-08-04

  • RHYTHM PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $26.06M, a 64.08% increase year-over-year.
  • RHYTHM PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $23.10M, a 79.59% increase year-over-year.
  • RHYTHM PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $19.27M, a 82.51% increase year-over-year.
  • RHYTHM PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $18.81M, a 70.98% increase year-over-year.
  • RHYTHM PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $66.82M, a 68.38% increase from fiscal 2024.
  • RHYTHM PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $39.68M, a 21.90% increase from fiscal 2023.
  • RHYTHM PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $32.55M, a 64.15% increase from fiscal 2022.
  • RHYTHM PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $19.83M, a 4.68% decline from fiscal 2021.
Period endShare-based Payment Arrangement, Noncash Expense 3 monthShare-based Payment Arrangement, Noncash Expense 6 monthShare-based Payment Arrangement, Noncash Expense 9 monthShare-based Payment Arrangement, Noncash Expense 12 month
2026-06-30$26.06M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04
$49.16M
10-Q · filed 2026-08-04
$68.42M
derived: sum of 3 quarters · filed 2026-08-04
$87.23M
derived: sum of 4 quarters · filed 2026-08-04
2026-03-31$23.10M
10-Q · filed 2026-05-05
$42.37M
derived: sum of 2 quarters · filed 2026-05-05
$61.17M
derived: sum of 3 quarters · filed 2026-05-05
$77.06M
derived: sum of 4 quarters · filed 2026-08-04
2025-12-31$19.27M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$38.08M
derived: sum of 2 quarters · filed 2026-02-26
$53.96M
derived: sum of 3 quarters · filed 2026-08-04
$66.82M
10-K · filed 2026-02-26
2025-09-30$18.81M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
$34.69M
derived: sum of 2 quarters · filed 2026-08-04
$47.55M
10-Q · filed 2025-11-04
$58.11M
derived: sum of 4 quarters · filed 2026-08-04
2025-06-30$15.88M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04
$28.74M
10-Q · filed 2026-08-04
$39.30M
derived: sum of 3 quarters · filed 2026-08-04
$50.30M
derived: sum of 4 quarters · filed 2026-08-04
2025-03-31$12.86M
10-Q · filed 2026-05-05
$23.42M
derived: sum of 2 quarters · filed 2026-05-05
$34.42M
derived: sum of 3 quarters · filed 2026-05-05
$44.78M
derived: sum of 4 quarters · filed 2026-05-05
2024-12-31$10.56M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$21.56M
derived: sum of 2 quarters · filed 2026-02-26
$31.91M
derived: sum of 3 quarters · filed 2026-02-26
$39.68M
10-K · filed 2026-02-26
2024-09-30$11.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
$21.36M
derived: sum of 2 quarters · filed 2025-11-04
$29.13M
10-Q · filed 2025-11-04
$37.80M
derived: sum of 4 quarters · filed 2026-02-26
2024-06-30$10.36M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05
$18.13M
10-Q · filed 2025-08-05
$26.80M
derived: sum of 3 quarters · filed 2026-02-26
$35.41M
derived: sum of 4 quarters · filed 2026-02-26
2024-03-31$7.77M
10-Q · filed 2025-05-07
$16.44M
derived: sum of 2 quarters · filed 2026-02-26
$25.05M
derived: sum of 3 quarters · filed 2026-02-26
$33.94M
derived: sum of 4 quarters · filed 2026-02-26
2023-12-31$8.67M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$17.29M
derived: sum of 2 quarters · filed 2026-02-26
$26.18M
derived: sum of 3 quarters · filed 2026-02-26
$32.55M
10-K · filed 2026-02-26
2023-09-30$8.61M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06
$17.50M
derived: sum of 2 quarters · filed 2024-11-06
$23.88M
10-Q · filed 2024-11-06
$29.17M
derived: sum of 4 quarters · filed 2025-02-28
2023-06-30$8.89M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06
$15.27M
10-Q · filed 2024-08-06
$20.55M
derived: sum of 3 quarters · filed 2025-02-28
$25.35M
derived: sum of 4 quarters · filed 2025-02-28
2023-03-31$6.38M
10-Q · filed 2024-05-07
$11.66M
derived: sum of 2 quarters · filed 2025-02-28
$16.46M
derived: sum of 3 quarters · filed 2025-02-28
$21.60M
derived: sum of 4 quarters · filed 2025-02-28
2022-12-31$5.29M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28
$10.08M
derived: sum of 2 quarters · filed 2025-02-28
$15.22M
derived: sum of 3 quarters · filed 2025-02-28
$19.83M
10-K · filed 2025-02-28
2022-09-30$4.80M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08
$9.93M
derived: sum of 2 quarters · filed 2023-11-08
$14.54M
10-Q · filed 2023-11-08
$19.22M
derived: sum of 4 quarters · filed 2024-02-29
2022-06-30$5.14M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01
$9.75M
10-Q · filed 2023-08-01
$14.42M
derived: sum of 3 quarters · filed 2024-02-29
$19.69M
derived: sum of 4 quarters · filed 2024-02-29
2022-03-31$4.61M
10-Q · filed 2023-05-02
$9.29M
derived: sum of 2 quarters · filed 2024-02-29
$14.55M
derived: sum of 3 quarters · filed 2024-02-29
$20.22M
derived: sum of 4 quarters · filed 2024-02-29
2021-12-31$4.68M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29
$9.94M
derived: sum of 2 quarters · filed 2024-02-29
$15.61M
derived: sum of 3 quarters · filed 2024-02-29
$20.80M
10-K · filed 2024-02-29
2021-09-30$5.27M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08
$10.94M
derived: sum of 2 quarters · filed 2022-11-08
$16.13M
10-Q · filed 2022-11-08
$20.39M
derived: sum of 4 quarters · filed 2023-03-01
2021-06-30$5.67M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03
$10.86M
10-Q · filed 2022-08-03
$15.12M
derived: sum of 3 quarters · filed 2023-03-01
$19.81M
derived: sum of 4 quarters · filed 2023-03-01
2021-03-31$5.19M
10-Q · filed 2022-05-03
$9.45M
derived: sum of 2 quarters · filed 2023-03-01
$14.14M
derived: sum of 3 quarters · filed 2023-03-01
$17.17M
derived: sum of 4 quarters · filed 2023-03-01
2020-12-31$4.26M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01
$8.95M
derived: sum of 2 quarters · filed 2023-03-01
$11.98M
derived: sum of 3 quarters · filed 2023-03-01
$17.45M
10-K · filed 2023-03-01
2020-09-30$4.70M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02
$7.72M
derived: sum of 2 quarters · filed 2021-11-02
$13.20M
10-Q · filed 2021-11-02
$16.12M
derived: sum of 4 quarters · filed 2021-11-02
2020-06-30$3.03M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03
$8.50M
10-Q · filed 2021-08-03
$11.43M
derived: sum of 3 quarters · filed 2021-08-03
$14.46M
derived: sum of 4 quarters · filed 2021-08-03
2020-03-31$5.47M
10-Q · filed 2021-05-03
$8.40M
derived: sum of 2 quarters · filed 2021-05-03
$11.43M
derived: sum of 3 quarters · filed 2021-05-03
$14.71M
derived: sum of 4 quarters · filed 2021-05-03
2019-12-31$2.92M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01
$5.96M
derived: sum of 2 quarters · filed 2021-03-01
$9.23M
derived: sum of 3 quarters · filed 2021-03-01
$11.88M
10-K · filed 2021-03-01
2019-09-30$3.04M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-02
$6.31M
derived: sum of 2 quarters · filed 2020-11-02
$8.95M
10-Q · filed 2020-11-02
$10.97M
derived: sum of 4 quarters · filed 2021-03-01
2019-06-30$3.27M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-03
$5.92M
10-Q · filed 2020-08-03
$7.94M
derived: sum of 3 quarters · filed 2021-03-01
$9.83M
derived: sum of 4 quarters · filed 2021-03-01
2019-03-31$2.64M
10-Q · filed 2020-05-04
$4.67M
derived: sum of 2 quarters · filed 2021-03-01
$6.56M
derived: sum of 3 quarters · filed 2021-03-01
$8.08M
derived: sum of 4 quarters · filed 2021-03-01
2018-12-31$2.02M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01
$3.92M
derived: sum of 2 quarters · filed 2021-03-01
$5.43M
derived: sum of 3 quarters · filed 2021-03-01
$6.39M
10-K · filed 2021-03-01
2018-09-30$1.89M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-01
$3.41M
derived: sum of 2 quarters · filed 2019-11-01
$4.37M
10-Q · filed 2019-11-01
$5.08M
derived: sum of 4 quarters · filed 2020-03-02
2018-06-30$1.52M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-29
$2.47M
10-Q · filed 2019-07-29
$3.18M
derived: sum of 3 quarters · filed 2020-03-02
$4.05M
derived: sum of 4 quarters · filed 2020-03-02
2018-03-31$958.00K
10-Q · filed 2019-05-03
$1.67M
derived: sum of 2 quarters · filed 2020-03-02
$2.54M
derived: sum of 3 quarters · filed 2020-03-02
$2.97M
derived: sum of 4 quarters · filed 2020-03-02
2017-12-31$709.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02
$1.58M
derived: sum of 2 quarters · filed 2020-03-02
$2.01M
derived: sum of 3 quarters · filed 2020-03-02
$2.28M
10-K · filed 2020-03-02
2017-09-30$871.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09
$1.30M
derived: sum of 2 quarters · filed 2018-11-09
$1.57M
10-Q · filed 2018-11-09
$1.88M
derived: sum of 4 quarters · filed 2019-03-08
2017-06-30$434.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08
$698.00K
10-Q · filed 2018-08-08
$1.01M
derived: sum of 3 quarters · filed 2019-03-08
2017-03-31$264.00K
10-Q · filed 2018-05-14
$573.00K
derived: sum of 2 quarters · filed 2019-03-08
2016-12-31$309.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-08
$1.17M
10-K · filed 2019-03-08
2016-09-30$859.00K
10-Q · filed 2017-11-14
2015-12-31$298.00K
8-K · filed 2018-11-09

Similar stocks

Stock NameCountryMarket CapPE Ratio
Alkermes plc. (ALKS)$6.844B132.74
Liquidia Corp (LQDA)United States$6.347B51.23
Amneal Pharmaceuticals, Inc. (AMRX)$6.326B25.62
IONIS PHARMACEUTICALS INC (IONS)United States$7.277B-23.25
Spyre Therapeutics, Inc. (SYRE)United States$7.685B-43.69
Structure Therapeutics Inc. (GPCR)United States$7.710B-53.41
Mirum Pharmaceuticals, Inc. (MIRM)United States$5.798B-8.81
Travere Therapeutics, Inc. (TVTX)United States$5.712B-123.10
Oruka Therapeutics, Inc. (ORKA)United States$5.663B-43.76
Praxis Precision Medicines, Inc. (PRAX)United States$7.884B-27.60